Plain-English translation of NCT04897321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing B7-H3-CAR T cells, a new type of immunotherapy made from a patient's own immune cells. Doctors remove T cells from the patient's blood, modify them in the laboratory to recognize and attack cancer cells, and then infuse them back into the patient's body. The trial is designed to find the safest and most effective dose of this treatment for children and young adults with solid tumors that have not responded to standard therapy.
Many children with solid tumors have cancers that stop responding to standard treatments like chemotherapy and surgery. This medication is being tested because early research suggests that using a patient's own modified immune cells might help fight these hard-to-treat cancers in a new way.
You likely qualify if…
You likely don't qualify if…
First, doctors will remove some of your blood cells through a procedure called apheresis, similar to donating plasma. These cells are then sent to a laboratory where they are genetically modified to recognize cancer cells. While the cells are being prepared, you will receive chemotherapy to prepare your body for the new cells. Once the modified cells are ready, you will receive them back as a single infusion through an IV. You will then be monitored closely for 6 weeks in the hospital and clinic for side effects and how well the treatment is working. After that, you will continue follow-up visits for a full year and then join a long-term follow-up program.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States